Rossari's margin slips to 11.6%, but management says that's the floor.
Q1 revenue rose 28% to ₹697 cr, but EBITDA margin fell 90 bps to 11.6%. The company now sees that as a near-term base and expects B2C exit to add 2-3 ppt.
— 1 earlier story on Rossari Biotech Ltd. →What's new
- EBITDA margin dropped 90 bps to 11.6% from 12.5% a year ago.
- Management revises margin floor guidance from 12-13% to current level.
- Ethylene oxide supply constrained; volume growth driven by non-EO products until December.
Why this matters
The margin slip confirms near-term pressure from institutional and consumer segments and rising costs. Yet the planned B2C exit and Thailand investment suggest management is addressing structural issues.
What we're watching
- Whether B2C exit delivers the promised 2-3 ppt margin release in coming quarters.
- Impact of EO supply normalisation expected by December on product mix.
- Pharma revenue guidance variability: from ₹30-50 crore to ₹70-75 crore adds uncertainty to FY27 revenue mix.
The full read
Revenue jumped 28% to ₹697 crore. Margins did not. EBITDA margin slipped 90 bps to 11.6%, weighed by institutional and consumer segments and higher freight and insurance costs — management now sees that as a near-term base, revising earlier guidance of a 12-13% floor. Ethylene oxide supply is constrained, so volume growth is coming from non-EO products until fresh material arrives before December. The B2C exit should free up 2-3 ppt of margin, and investments in Thailand and R&D target longer-term recovery, but pharma revenue guidance varied widely from ₹30-50 crore to ₹70-75 crore during the call. FY27 revenue growth guidance stays at 15%. The margin floor has moved lower, but the portfolio reset is in motion.
Questions answered
- Why did Rossari's EBITDA margin fall despite strong revenue growth?
- Margin slipped due to higher freight and insurance costs and pressure from institutional and consumer segments. Management now sees 11.6% as a near-term floor.
- What is Rossari doing to recover margins?
- It is exiting B2C consumer activities, which should release 2-3 ppt of EBITDA margin. It is also investing in a Thailand blending plant and R&D for longer-term recovery.
- What is the status of ethylene oxide supply?
- EO supply remains constrained, so volume growth is coming from non-EO products. Additional material is expected before December.
- What is the FY27 revenue growth guidance?
- Management reaffirmed 15% revenue growth for FY27. However, pharma revenue guidance varied during the call, ranging from ₹30-50 crore to ₹70-75 crore.
Rossari Biotech Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on ROSSARI →- 20 Jul 2026 · 6:16 PM IST Rossari's margin slips to 11.6%, but management says that's the floor.
- 3d ago Rossari Q1 revenue up 28% to ₹6,972M; profit rises but dips sequentially